CN104603090A - 治疗代谢综合征的组合物和方法 - Google Patents

治疗代谢综合征的组合物和方法 Download PDF

Info

Publication number
CN104603090A
CN104603090A CN201380030661.2A CN201380030661A CN104603090A CN 104603090 A CN104603090 A CN 104603090A CN 201380030661 A CN201380030661 A CN 201380030661A CN 104603090 A CN104603090 A CN 104603090A
Authority
CN
China
Prior art keywords
administration
compositions
complications
diabetes
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380030661.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·坎杜拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of CN104603090A publication Critical patent/CN104603090A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380030661.2A 2012-05-10 2013-02-03 治疗代谢综合征的组合物和方法 Pending CN104603090A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1835/CHE/2012 2012-05-10
IN1835CH2012 2012-05-10
PCT/IB2013/050904 WO2013167996A1 (fr) 2012-05-10 2013-02-03 Compositions et méthodes de traitement du syndrome métabolique

Publications (1)

Publication Number Publication Date
CN104603090A true CN104603090A (zh) 2015-05-06

Family

ID=54193697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030661.2A Pending CN104603090A (zh) 2012-05-10 2013-02-03 治疗代谢综合征的组合物和方法

Country Status (7)

Country Link
EP (1) EP2847152A4 (fr)
JP (1) JP2015521184A (fr)
CN (1) CN104603090A (fr)
AU (1) AU2013257717A1 (fr)
CA (1) CA2873089A1 (fr)
SG (1) SG11201407411SA (fr)
WO (1) WO2013167996A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107751996A (zh) * 2017-09-29 2018-03-06 赤峰赛佰诺制药有限公司 一种用于尿素循环障碍的配方粉及其制备方法
CN107751999A (zh) * 2017-09-29 2018-03-06 赤峰赛佰诺制药有限公司 一种用于异戊酸血症的配方粉及其制备方法
CN107772459A (zh) * 2017-09-29 2018-03-09 赤峰赛佰诺制药有限公司 一种用于枫糖尿症的配方粉及其制备方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
WO2013167992A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles inflammatoires
WO2013168023A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de la maladie de parkinson
WO2013167991A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles métaboliques
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2013167997A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168016A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur chronique
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175344A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
CA2873098A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la sclerose en plaques
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (fr) 2012-08-03 2014-02-06 Mahesh Kandula Compositions et méthodes pour le traitement de la migraine et de maladies neurologiques
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (fr) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions et methodes de traitement d'une inflammation et de troubles lipidiques
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (fr) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions et procedes de traitement du diabete et du pre-diabete
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (fr) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (fr) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
US11400066B2 (en) 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
EP3852739A1 (fr) * 2018-09-20 2021-07-28 Institut Pasteur De Montevideo Procédés de traitement d'états associés à une inflammation à l'aide de modulateurs anti-inflammatoires et métaboliques pluripotents
CN114324674A (zh) * 2022-01-21 2022-04-12 苏州南医大创新中心 一种精液中与无精子症有关的分子标志物及其检测方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1368879A (zh) * 1999-06-04 2002-09-11 麦它波莱克斯股份有限公司 (－)(3－三卤代甲基苯氧基)(4－卤代苯基)乙酸衍生物在治疗耐胰岛素、2型糖尿病、高脂血症和高尿酸血症中的应用
WO2009046371A1 (fr) * 2007-10-05 2009-04-09 Metabolex, Inc. Procédés de traitement de maladies métaboliques
WO2011089216A1 (fr) * 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de dipeptides pour des médicaments contenant des amines aliphatiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517050A (en) * 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
JP2008533206A (ja) * 2005-03-21 2008-08-21 メタボレックス インコーポレーティッド 代謝、炎症、および心血管障害の処置における浮腫を回避するための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1368879A (zh) * 1999-06-04 2002-09-11 麦它波莱克斯股份有限公司 (－)(3－三卤代甲基苯氧基)(4－卤代苯基)乙酸衍生物在治疗耐胰岛素、2型糖尿病、高脂血症和高尿酸血症中的应用
WO2009046371A1 (fr) * 2007-10-05 2009-04-09 Metabolex, Inc. Procédés de traitement de maladies métaboliques
WO2011089216A1 (fr) * 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de dipeptides pour des médicaments contenant des amines aliphatiques

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107751996A (zh) * 2017-09-29 2018-03-06 赤峰赛佰诺制药有限公司 一种用于尿素循环障碍的配方粉及其制备方法
CN107751999A (zh) * 2017-09-29 2018-03-06 赤峰赛佰诺制药有限公司 一种用于异戊酸血症的配方粉及其制备方法
CN107772459A (zh) * 2017-09-29 2018-03-09 赤峰赛佰诺制药有限公司 一种用于枫糖尿症的配方粉及其制备方法

Also Published As

Publication number Publication date
CA2873089A1 (fr) 2013-11-14
EP2847152A4 (fr) 2016-03-23
EP2847152A1 (fr) 2015-03-18
SG11201407411SA (en) 2014-12-30
AU2013257717A1 (en) 2014-11-27
WO2013167996A1 (fr) 2013-11-14
JP2015521184A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
CN104603090A (zh) 治疗代谢综合征的组合物和方法
CN104583182A (zh) 用于治疗粘膜炎的组合物和方法
CN105612155A (zh) 治疗局部疼痛的组合物和方法
CN104603100A (zh) 用于治疗炎症性肠病的组合物和方法
CN104364241A (zh) 抑制碳酸酐酶活性的组合物和方法
WO2014087307A2 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
CN104350041A (zh) 用于治疗神经系统疾病的组合物和方法
CN104603097A (zh) 用于治疗多发性硬化症的组合物和方法
JP2015518854A5 (fr)
CN104583162A (zh) 治疗中度至重度疼痛的组合物和方法
CN104364230A (zh) 用于治疗糖尿病的组合物和方法
WO2014080307A2 (fr) Compositions et procédés pour le traitement du diabète et du pré-diabète
CN104797568A (zh) 用于治疗神经障碍的组合物和方法
RU2751770C2 (ru) Композиции и способы лечения синдрома раздраженного кишечника
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
US9315478B2 (en) Compositions and methods for the treatment of metabolic syndrome
CN104812737A (zh) 用于治疗高血糖症的组合物和方法
CN104379589A (zh) 抗血小板药剂的前药
WO2014053962A2 (fr) Compositions et méthodes de traitement du diabète et du prédiabète
US9309233B2 (en) Compositions and methods for the treatment of blood clotting disorders
WO2015022613A1 (fr) Compositions et méthodes pour le traitement du diabète et du pré-diabète
CN104364231A (zh) 用于治疗炎症和脂质异常的组合物和方法
US9321716B1 (en) Compositions and methods for the treatment of metabolic syndrome
WO2014037833A2 (fr) Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
WO2014147541A2 (fr) Compositions et méthodes pour le traitement des ulcères gastro-duodénaux et des maladies gastro-intestinales

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150506

WD01 Invention patent application deemed withdrawn after publication